Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

A proteomic signature associated to atypical antipsychotic response in schizophrenia patients: a pilot study

Full text
Author(s):
Martins-de-Souza, Daniel [1, 2, 3] ; Guest, Paul C. [1] ; Steiner, Johann [4, 5, 6]
Total Authors: 3
Affiliation:
[1] Univ Campinas UNICAMP, Lab Neuroprote, Dept Biochem & Tissue Biol, Inst Biol, RuaMonteiroLobato 255, BR-13083862 Campinas, SP - Brazil
[2] Conselho Nacl Desenvolvimento Cient & Tecnol CNPq, Inst Nacl Biomarcadores Neuropsiquiatr INBION, Sao Paulo - Brazil
[3] UNICAMP Neurobiol Ctr, Campinas - Brazil
[4] Univ Magdeburg, Dept Psychiat & Psychotherapy, Magdeburg - Germany
[5] Univ Magdeburg, Lab Translat Psychiat, Magdeburg - Germany
[6] CBBS, Magdeburg - Germany
Total Affiliations: 6
Document type: Journal article
Source: EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE; v. 270, n. 1, p. 127-134, FEB 2020.
Web of Science Citations: 0
Abstract

A major hurdle faced by most schizophrenia patients is the poor efficacy of current antipsychotic medications. This stems from a poor understanding of the underlying pathophysiology and the lack of biomarkers for the prediction of a positive medication response. By employing state-of-the-art proteomic analysis of blood plasma from 58 patients who were either drug-naive or drug-free at the time of sample collection, we identified potential biomarkers that were predictive of a positive response after 6 weeks of treatment with antipsychotics. Complement and coagulation cascades were the most over-represented biological pathways among these proteins, consistent with the importance of these processes in schizophrenia. Although preliminary, these findings are novel and may drive future efforts in the development of predictive tests for medication efficacy and thereby have a positive influence on disease outcome. (AU)

FAPESP's process: 17/25588-1 - From the basic understanding to clinical biomarkers to schizophrenia: a neuroproteomics-centered multidisciplinary study
Grantee:Daniel Martins-de-Souza
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 13/08711-3 - Developing a predictive test for a successful medication response and understanding the molecular bases of schizophrenia through proteomics
Grantee:Daniel Martins-de-Souza
Support Opportunities: Research Grants - Young Investigators Grants